SF-6D量表效用值积分体系构建方法及结果的国际比较
International comparison of the development methods and results of the SF-6D value sets
胡宏飞 1李冯 1周挺2
作者信息
- 1. 中国药科大学国际医药商学院,南京 211198
- 2. 中国药科大学国际医药商学院,南京 211198;中国药科大学药物经济学评价研究中心,南京 211198
- 折叠
摘要
随着药物经济学评价在卫生决策中的应用不断深入,如何科学推动药物经济学评价工作高质量开展变得愈发重要.健康相关生命质量,特别是健康效用值作为药物经济性评价中成本-效用分析的重要组成部分,开展相关研究能够更好地为提升药物经济学评价证据的质量提供支持.尽管目前基于我国人群健康偏好已构建六维健康调查短表(short-form six-dimensions,SF-6D)效用积分体系,但缺乏不同国家或地区间的全面比较研究.因此本研究系统介绍了中国、英国、澳大利亚等12个国家或地区SF-6D量表效用积分体系的构建方法,并对研究结果进行比较,以期推动SF-6D量表和其他同类量表在我国后续开展相关研究和应用,为科学决策提供支持.
Abstract
With the increasing application of pharmacoeconomic evaluation evidence in health decision-making,it highlights the need of improving the quality.Health-related quality of life,especially health utility value,plays an important role in cost-utility analysis.Conducting relevant research can significantly contribute to improving the quality of evidence for pharmacoeconomic evaluation.Although the Chinese SF-6D value set has been estimated based on the health preferences of local population,there lack comprehensive comparative studies across different countries or regions.To facilitate the further research and application of the SF-6D and other similar scales in China,and to inform better decision-making,this study systematically compared the estimation method and final recommendation of the SF-6D utility value sets in 12 countries or regions such as China,UK,Australia and others.
关键词
六维健康调查短表/积分体系/健康相关生命质量/药物经济学Key words
short-form six-dimensions/value set/health-related quality of life/pharmacoeconomic引用本文复制引用
出版年
2024
NETL
NSTL
万方数据